Dexmedetomidine for treatment of hyperactive delirium in non‑intubated ICU patients: the 4D randomized clinical trial

PRODUCT LITERATURE

Dexmedetomidine for treatment of hyperactive delirium in non‑intubated ICU patients: the 4D randomized clinical trial

Godet T - Personal Name;

In a multicenter, double-blind, placebo-controlled, two-arm, investigator-initiated, randomized trial conducted in 9 ICUs, we randomly assigned non-intubated critically ill adults with hyperactive delirium to receive continuous intravenous infusion of dexmedetomidine or placebo for at least 36 h. The primary outcome was a joint modelling of multiple outcomes of agitation duration (score of + 1 or higher on the Richmond agitation-sedation scale), delirium duration, or the need for intubation and deep sedation. Key secondary outcomes included the occurrence of complications (such as bradycardia or hypotension), length of stay in ICU, or death.

Availability

No copy data

Detail Information

Series Title: -
Call Number: -
Publisher: : .,
Collation: -
Language: English
ISBN/ISSN: -
Classification: NONE
Content Type: -
Media Type: -
Carrier Type: -
Edition: -
Subject(s): Dexmedetomidine
Specific Detail Info: -
Statement of Responsibility: -

Other version/related

No other version available

File Attachment

Read Here

Comments

You must be logged in to post a comment